Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches Keymed Biosciences achieved remarkable financial results in 2025, marking a significant increase in revenue alongside successful product launches and clinical advances.

Keymed Biosciences Reports Impressive Annual Results for 2025 with Growth in Revenue and Product Launches #China #Beijing #Clinical_Trials #Keymed_Biosciences #Kangyueda

Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision Keymed Biosciences has shared its annual financial results for 2025, highlighting a significant increase in revenue and breakthroughs in its product offerings.

Keymed Biosciences Reports Their 2025 Annual Financial Results and Future Vision #China #Beijing #Keymed_Biosciences #Kangyueda #CMG901

Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments Keymed Biosciences has announced strong financial results for 2025, showcasing impressive revenue growth and strategic advancements in its product pipeline.

Keymed Biosciences Reports Significant Revenue Growth for 2025 and Updates on Business Developments #China #Beijing #Keymed_Biosciences #Kangyueda #CMG901

Keymed Biosciences Gains Approval for Stapokibart, a New Drug for Seasonal Allergic Rhinitis Keymed Biosciences has received approval for Stapokibart, a drug to treat seasonal allergic rhinitis, marking a significant advancement in allergy treatment.

Keymed Biosciences Gains Approval for Stapokibart, a New Drug for Seasonal Allergic Rhinitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyps Keymed Biosciences has announced that Stapokibart, a monoclonal antibody, has been approved for the treatment of chronic rhinosinusitis with nasal polyps in China, based on positive clinical trial results.

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis with Nasal Polyps #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis Keymed Biosciences has announced that China's NMPA approved Stapokibart for chronic rhinosinusitis with nasal polyposis, showcasing significant clinical efficacy.

Keymed Biosciences Receives Approval for Stapokibart to Treat Chronic Rhinosinusitis #China #Chengdu #Keymed_Biosciences #Stapokibart #Kangyueda